47 results on '"West, Michael L."'
Search Results
2. Retrospective review of recent ASA prescribing practices for primary prevention of major adverse cardiovascular events in the Canadian Fabry Disease Initiative cohort
3. FollowME Fabry Pathfinders Registry: Renal effectiveness in a cohort of patients on migalastat treatment for at least three years
4. Glycosphingolipid evaluation for Fabry disease patients receiving migalastat after switching from enzyme replacement therapy
5. Chest pain subtype prevalence in the British Columbia cohort of the Canadian Fabry Disease Initiative
6. Facilitating intrafamily communication to enable earlier diagnosis of Fabry disease in relatives: Expert opinion
7. Switch from enzyme replacement therapy to pharmacologic chaperone: Improvement in advanced Fabry nephropathy
8. The spectrum of podocyte injury in later onset (LO) variants of Fabry disease (FD)
9. FollowME Fabry Pathfinders registry: Renal effectiveness in a multi-national, multi-center cohort of patients on migalastat treatment for at least three years
10. Clinical characteristics of female patients enrolled in the FollowME Fabry Pathfinders registry
11. Corrigendum to “Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing” [2021 Sep-Oct;134(1–2):117–131]
12. Long-term outcomes in patients with Fabry disease who were treated with agalsidase alfa for more than nineteen years: The Fabry Outcome Survey
13. Early therapy in Fabry disease: Outcomes from the Canadian Fabry Disease Initiative (CFDI) registry
14. Early initiation of agalsidase alfa treatment improves clinical outcomes in male patients with classical Fabry disease: A Fabry Outcome Survey (FOS) analysis
15. Persistent Hematopoietic Polyclonality after Lentivirus-mediated Gene Therapy for Fabry Disease
16. Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing
17. Canadian Fabry disease registry study group: Report on the A143P Nova Scotia genotype
18. Lyso Gb3 and Gb3 analogues in Fabry disease patients with A143P genotype: A cross-sectional analysis by the CFDR study group
19. Independent Registries Are Cost-Effective Tools to Provide Mandatory Postauthorization Surveillance for Orphan Medicinal Products
20. Therapeutic challenges in two adolescent male patients with Fabry disease and high antibody titres
21. Routes to diagnosis of Fabry disease according to patient age and geographic distribution
22. Determination of the crystal structure and substrate specificity of ananain
23. Valvular heart disease complicating advanced Fabry disease: Association with chronic kidney disease
24. FACTs Fabry gene therapy clinical trial: Two-year data
25. Renal and cardiac outcomes in female patients with Fabry disease treated with agalsidase beta: A Fabry registry analysis of pre- versus post-treatment comparison
26. Long-term outcomes with agalsidase alfa enzyme replacement therapy: Analysis using deconstructed composite events
27. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: An international cohort study
28. Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34 + Cells for Correction of Fabry Disease
29. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
30. Tetrahydrobiopterin deficiency in the pathogenesis of Fabry disease
31. Chronic kidney disease and an uncertain diagnosis of Fabry disease: Approach to a correct diagnosis
32. Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry
33. Consensus recommendation on Fabry disease diagnosis in adult patients with kidney disease
34. Gene therapy for Fabry disease patients: The importance of efficient biomarker monitoring
35. Cardiovascular Events in Patients With Fabry Disease
36. How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?
37. Therapeutic goals in the treatment of Fabry disease
38. Effects of enzyme replacement therapy in Fabry disease—A comprehensive review of the medical literature
39. CARDIOVASCULAR EVENTS IN PATIENTS WITH FABRY DISEASE: NATURAL HISTORY DATA FROM THE FABRY REGISTRY
40. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease
41. The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease
42. Diagnosis and Management of Kidney Involvement in Fabry Disease
43. Patients with Fabry disease on dialysis in the United States
44. A novel method for solid-phase synthesis of oligosaccharides using the N -1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl (Dde) linker
45. Targeting HIV-1 protease: A test of drug-design methodologies
46. Ethical And Moral Issues In Nephrology
47. A controlled trial of cyclophosphamide in patients with membranous glomerulonephritis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.